The growing use of AI‑driven modeling in clinical development is exposing how limited traditional, single‑study dose selection and patient assessment methods have been for complex oncology programs. In this episode, Shefali Kakar, Global Head of PK Sciences and Oncology at Novartis, examines how deeper data integration across phases enables more precise dose decisions, clearer safety interpretation, and a more consistent understanding of patient variability alongside host Matthew DeMello. She outlines how longitudinal analysis, exposure–response modeling, and covariate evaluation are helping teams reduce unnecessary sub‑studies, tailor dosing for diverse patient groups, and strengthen cross‑functional decision‑making throughout development. According to Nielsen, 91% of podcast listening happens alone, creating a focused, distraction-light environment well suited for complex B2B messaging. Learn how leading brands and AI startups connect with enterprise AI buyer audiences at scale by downloading our media kit at go.emerj.com/partner

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related